Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $12

Author: Benzinga Newsdesk | August 07, 2024 12:12pm
Craig-Hallum analyst Alexander Nowak maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $9 to $12.

Posted In: BVS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist